Open Orphan to conduct first-ever COVID-19 human challenge trial
pharmafile | October 21, 2021 | News story | Business Services |
Open Orphan has announced that they are progressing with their government-backed COVID-19 vaccine human challenge study.
The company has signed a £5.7 million contract for a challenge study for a biotech company developing an anti-flu treatment.
The in-human study is scheduled for the first quarter of 2022, and it will be conducted at subsidiary hVIVO’s state-of-the-art facilities in London, as well as its 19-bedroom Whitechapel hotel clinic, using specialised on-site virology and immunology laboratory.
Open Orphan expects the revenue from the contract to be recognised across 2021 and 2022, and will boost the income expected as demand for challenge trials increases.
“Post-pandemic, the infectious and respiratory disease market is seeing exponential growth, with an expected global market value of $250 billion by 2025,” the company said in a statement.
Last month, Open Orphan announced the positive results from a Phase II respiratory syncytial virus (RSV) human challenge study conducted by its hVIVO arm. Data released by Barvarian Nordic showed a significant reduction in viral load in people who were vaccinated.
Open Orphan is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to major names such as Big Pharma, as well as other biotech and government/public health organisations.
The company has a leading portfolio of human challenge studies for infectious and respiratory diseases, and is developing a number of new models. Building on their accumulated years of challenge studies and experience with virology research, the company is developing an in-depth database of infectious disease progression data.